GENEXI

GENEXI

Created using Figma
GEN tokens are neither a debt instrument nor a bond in any form, nor any other form of loan. Holders of tokens do not have the right to distribute financial or any other assets of the Platform, and the token holders do not have the right to own or share in the capital of the Platform. Also GEN tokens do not give holders the right to vote, the right to receive dividends and the right of distribution of the proceeds of the Platform. GEN tokens are not refundable, the token holders are not given the opportunity to receive compensation in cash or otherwise. The GEN token is not provided with any guarantees as to its future value.
The profound commercial potential of biotechnology cannot remain unnoticed. Multiple states and international companies have made substantial investments into research and development (R&D) of life sciences and biotechnology: currently, medical biotech, with revenues exceeding $150 billion annually, receives a bulk of biotech investment and research dollars. Medical Biotech has contributed to the discovery and manufacturing of traditional small molecule pharmaceutical drugs along with drugs that are products of biotechnology – biopharmaceutics. Modern biotechnology can be applied to make the production of existing medicines relatively easy and cheap. The traditional interactions in the biotech market can also be induced by the use of modern
technologies that would enable smoother operations between producers, retailers and consumers, while one of the major targets in today’s conditions is ensuring a provision of detailed immutable data and transparency of research.
  • Market
    Pair
    Price
    Volume 24H
    24H (price)
    24H (volume)
  • Hotbit
    GXI/BTC 3 one year ago
    $ 0.0002
    $ 0.9265
    -
    -
Jun 1, 2018
Aug 31, 2018
100% completed
$9 158 228
100% goal completed
past
May 1, 2018
May 31, 2018
100% completed
Raised funds - no Data
past
Token Details
Total supply
8,400,000,000
Token Distribution
70% - Public Distribution
10% - Long-term Foundation Budget
15% - Founders, Team
5% - Advisors and Early Contributors
Accepted Currencies
ETH, BTC, LTC, BCH, XMR, USDT, DSH, B2B
Company Details
Registered Company Name
GENEXI
Registered Country
Switzerland
Bonus Structure
Pre-Sale Round: 20% bonus
Token Sale Round 1: 17% bonus
Token Sale Round 2: 9% bonus
Token Sale Round 3: 5% bonus
Token Sale Round 4: 2% bonus
Additional Details
MVP/Prototype
Yes
KYC
Yes
Categories
Platform, Health, Big Data

About GENEXI

GENEXI is a biotech accelerator that operates both as a platform and foundation supporting researchers and entrepreneurs in the field as well as further developing biotech community.

GENEXI combines the expertise of renowned specialists in the biotech industry to create a thriving ecosystem for biotech strartups and established pharmaceutical companies of different sizes and levels of operation.
GENEXI Foundation is an organisation employing a wide range of high-profile biotech professionals to provide manual heuristic analysis for the most detailed venture assessment and evaluation.
GENEXI Foundation will use its expertise and funds to select the most promising biotech startups for grant awarding.
GENEXI Platform is an innovative solution provided by the GENEXI Dev Team for the e-commerce market in order to support GENEXI Ecosystem development. The Platform will unite biotech producers, distributors, retailers and end-consumers in one blockchain-based solution operating as a global
ecosystem.

There are several fundamental issues in the biotech industry, such as quality assurance, counterfeiting, research intransparency. The problems caused by the intermediaries cannot be ignored either.
GENEXI is determined to bring about a holistic solution in the form of a transparent and comprehensive blockchain-based ecosystem on to the market.
Within GENEXI Ecosystem such entities as biotech start-ups and projects will be able to find financlial and advisory support to establish or scale-up their production and then enter the GENEXI Platform Marketplace, distributors will be able to provide their services and build networks with vendors, while regular customers will gain an access to complete immutable data about the products. At the same time, third-party service providers will be able to present their support to other participants within the ecosystem. All the economic interactions within the ecosystem, such as payments, transactions, cashback programs will use the GEN token as its core currency.
GENEXI is also integrating its know-how solution for shipment tracking, QA and Authenticity Verification in order to fight counterfeit, fraud and quality manipulation. Such blockchain-based solutions will be incorporated into every stage of production and shipment process to ensure full transparency of the product delivery and distribution.

GENEXI Roadmap

  • 2014

  • Primary Scientific and Medical Research.
  • Q1 2017

  • GENEXI Establishment.
  • Q3 2017

  • Ecosystem and Platform Development.
  • Q1 2018

  • Low Level Design Launch.
  • Read More
  • Q3 2018

  • Ecosystem Alpha Version Testing.
  • Q4 2018

  • Smart-Contract Development and Testing. Grant Application Program Launch.
  • H1 2019

  • Ecosystem Complete Version Launch.
  • H2 2019

  • Official Public GENEXI Accelerator Report.
  • 2020

  • Further Ecosystem Development and Scaling.

GENEXI Materials

GENEXI Team

Verified 0%

Attention. There is a risk that unverified members are not actually members of the team

Katrina Arden
Escrow
unverified
Alexey Zhelyaskov
Founder, CEO
unverified
Alexey Kirillov
Co-Founder, COO
unverified
Roman Gilvanov
Roman Gilvanov
unverified
Sergey Tiurin
Head of Medical Research
unverified
Andrew Zharkov
Head of Finance
unverified
Alexey Nosikov
Head of Operations
unverified
Andrew Marcus
Head of Strategy
unverified
Bogdan Stepanov
Head of Business Development
unverified
Anton Sklovets
Head of Research
unverified
Daria Goriychuk
Head of HR
unverified
Alexander Novoselov
Biotech Analyst
unverified
Anton Nizhenkov
Investment Analyst
unverified
Dennis Sarkar
Ecosystem Developer
unverified
Jacques Miabouna
Strategy Consultant
unverified
Vladimir Stark
Head of Marketing
unverified
Anastasia Verbitskay...
Community Manager
unverified
Denis Baldakov
Community Manager
unverified
Stepan Razenkov
Community Manager
unverified
Anna Rafaelli
Chief Editor
unverified
Inna Leonova
Graphic Designer
unverified
Anna Fursova
PR Manager
unverified
Margarita Ilina
PR Manager
unverified
Egor Stepanov
Head of IT
unverified
Alexander Abarevich
Technical Support Lead
unverified

Advisors

Verified 0%

Attention. There is a risk that unverified members are not actually members of the team

Anti Danilevski
ICO advisor
unverified
Malcolm Tan
Advisor
unverified
Roel Wolfert
Advisor
unverified
Philip Mcmaster
Advisor
unverified

GENEXI Last News

  • Due to potential time differences in information updates, please verify the accuracy of each ICO project through its official website or other official communication channels.
  • This information is not intended as a recommendation or suggestion for ICO investment. Please conduct thorough research on the relevant information and make your own informed decision regarding ICO participation.
  • If you identify any issues or errors in this content, or if you wish to submit your own ICO project for listing, please contact us via email at info@icoholder.com.
Please read the disclaimer and risk warning. Show disclaimer and risk warning.